The reimbursement period for the Alimta+Keytruda+platinum-based chemotherapy is set to be extended. Previously, the 3-drug combination was covered for up to 2 years, but the Cancer Disease Deliberation Committee decided to remove this restriction from the reimbursement standards.

The Health Insurance Review and Assessment Service announced that it had made the decision above at the 2nd 2024 Cancer Disease Review Committee meeting that was held on March 6.

After deliberations, the CDDC decided to remove the maximum 2-year coverage restriction set for pemetrexed drugs such as Alimta Inj used in combination with pembrolizumab and platinum-based chemotherapy as first-line treatment for patients